Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Gazzard

Showing results (201-210 of 221) with videos related to

Pageof 23
Sort By:
AIDS Care|July 23, 2013
Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunitiesT J Barber, D Bradshaw, D Hughes, et al.
HIV Medicine|November 16, 2006
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)B Gazzard, A J Bernard, M Boffito, et al.
HIV Medicine|March 16, 2013
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA)S Fidler, J Anderson, Y Azad, et al.
Journal of Viral Hepatitis|October 21, 2009
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomesJ Turner, L Bansi, R Gilson, et al.
HIV Medicine|January 18, 2008
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UKP J Easterbrook, A N Phillips, T Hill, et al.
The Journal of Infectious Diseases|June 9, 2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected personsA I Veldkamp, M Harris, J S Montaner, et al.
HIV Medicine|November 9, 2010
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters, M Fisher, J Anderson, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
HIV Medicine|September 27, 2003
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyA Pozniak, B Gazzard, J Anderson, et al.
HIV Medicine|November 24, 2011
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UKC Kober, M Johnson, M Fisher, et al.
Pageof 23

Showing results (201-210 of 221) with videos related to

Sort By:
Pageof 23
AIDS Care|July 23, 2013
Screening for HIV-related neurocognitive impairment in clinical practice: challenges and opportunitiesT J Barber, D Bradshaw, D Hughes, et al.
HIV Medicine|November 16, 2006
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)B Gazzard, A J Bernard, M Boffito, et al.
HIV Medicine|March 16, 2013
Position statement on the use of antiretroviral therapy to reduce HIV transmission, January 2013: the British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA)S Fidler, J Anderson, Y Azad, et al.
Journal of Viral Hepatitis|October 21, 2009
The prevalence of hepatitis C virus (HCV) infection in HIV-positive individuals in the UK - trends in HCV testing and the impact of HCV on HIV treatment outcomesJ Turner, L Bansi, R Gilson, et al.
HIV Medicine|January 18, 2008
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UKP J Easterbrook, A N Phillips, T Hill, et al.
The Journal of Infectious Diseases|June 9, 2001
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected personsA I Veldkamp, M Harris, J S Montaner, et al.
HIV Medicine|November 9, 2010
Responses to highly active antiretroviral therapy and clinical events in patients with a low CD4 cell count: late presenters vs. late startersL Waters, M Fisher, J Anderson, et al.
HIV Medicine|November 21, 2008
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapyC A Sabin, C J Smith, V Delpech, et al.
HIV Medicine|September 27, 2003
British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapyA Pozniak, B Gazzard, J Anderson, et al.
HIV Medicine|November 24, 2011
Non-uptake of highly active antiretroviral therapy among patients with a CD4 count < 350 cells/μL in the UKC Kober, M Johnson, M Fisher, et al.
Pageof 23